Amin Talati Upadhye’s “Brand to Generic Drug Practice” prime focus is strategy and execution. ATU counsels both brand companies [505(b)(2) applicants] seeking to strategically patent and launch their brand name products in the long term; and to generic companies seeking to challenge patents and bring drugs to market. ATU provides input at every stage of the product lifecycle from product selection, R&D, regulatory affairs, product launch, and ongoing marketing/sales. We have great success in court litigations and FDA compliance. The Group is led by Shashank Upadhye, a trusted advisor to companies and widely recognized as one of the leading Hatch-Waxman Paragraph IV attorneys in the country.